146726-10-5

Basic information

• Product Name: (1R,5S,6r)-3-benzyl 6-ethyl 3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate
• Synonyms: (1R,5S,6r)-3-benzyl 6-ethyl 3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate;MXEJHXZQYANNJK-HPNRGHHYSA-N
• CAS NO: 146726-10-5
• Molecular Formula: C₁₆H₁₉NO₄
• Molecular Weight: 289.32636
• Mol File: 146726-10-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1R,5S,6r)-3-benzyl 6-ethyl 3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1R,5S,6r)-3-benzyl 6-ethyl 3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate(146726-10-5)
• EPA Substance Registry System: (1R,5S,6r)-3-benzyl 6-ethyl 3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate(146726-10-5)

Safety Data

• Hazardous Substances Data: 146726-10-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(1R,5S,6R)-3-benzyl 6-ethyl 3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate is used as a potential pharmaceutical agent for its unique molecular structure that may exhibit beneficial biological activities. Further research and testing are required to explore its full potential and understand its effects on various biological systems.

Upstream product

• 174456-77-0 [(1α,5α,6α)-3-aza-bicyclo[3.1.0]hexane]-6-carboxylic acid ethyl ester 
• 501-53-1 benzyl chloroformate 
• 31970-04-4 1-carboxybenzyl-3-pyrrolidine 
• 134575-06-7 ethyl (1α,5α,6α)-3-benzyl-3-azabicyclo[3.1.0]hexane-2,4-dione-6-carboxylate 
• 623-73-4 diazoacetic acid ethyl ester 

Downstream Products

• 134575-14-7 benzyl (1α,5α,6α)-6-hydroxymethyl-3-azabicyclo[3.1.0]hexan-3-ylcarboxylate 
• 134575-17-0 tert-butyl (1R,5S,6R)-3-azabicyclo[3.1.0]hexan-6-ylcarbamate 
• 504438-08-8 (1R,55,6r)-benzyl 6-formyl-3-azabicyclo^3.1.0hexane-3-carboxylate 
• 681425-64-9 (1S,5R,6s)-benzyl 6-vinyl-3-azabicyclo^3.1.0hexane-3-carboxylate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF

(I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transfection (RET), potentially useful in the treatment of RET-associated diseases, such as RET-associated cancers.

DEUTERATED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IMAGING AGENTS

The present invention relates to deuterated and optionally detectably labeled compounds of formula (I): R1-A-R2 and formula (V) and salts thereof, wherein Rl, R2, A, and X10-X19 have any of

Synthesis and diacylglycerol acyltransferase-1 inhibition of azabicyclo[3.1.0]hexane derivatives

We identified azabicyclo[3.1.0]hexane derivatives that are active diacylglycerol acyltransferase-1 (DGAT)-1 inhibitor. Among the azabicyclo[3.1.0]hexane series, compound 6b showed good in vitro activity toward human DGAT-1, selectivity toward DGAT-2, and

INDOLE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS

Disclosed are the CCR2 antagonists of Formula I: I or pharmaceutically acceptable salt thereof wherein R7, A, X, B, and n are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds

SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES USEFUL AS CCR2 ANTAGONISTS

Disclosed are CCR2 antagonists of Formula (I)or pharmaceutically acceptable thereof, wherein R1, L1 and A are defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and compositions to treat diseases or disorders associated with CCR2 activity.

6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES

The present invention relates to 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

Conformational constraint in oxazolidinone antibacterials. Synthesis and structure-activity studies of (azabicyclo[3.1.0]hexylphenyl)oxazolidinones

The oxazolidinones are a new class of synthetic antibacterials effective against a broad range of pathogenic Gram-positive bacteria, including multi-drug-resistant strains. Linezolid is the first drug from this class to reach the market and has become an

Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones

This invention relates to certain azabicyclo hexane intermediates and processes for making and using the azabicyclo hexane intermediates. The intermediates are useful in the synthesis of quinolone antibacterial agents.

Azabicyclo quinolone carboxylic acids

Quinolone carboxylic acids 7-substituted by azabicyclo groups have antibacterial activity., Antibacterial wherein, R1 is hydrogen, a pharmaceutically acceptable cation, or alkyl;, Y, when taken independently, is ethyl, t-butyl, vinyl, cyclopropyl, 2-fluoroethyl, p-fluorophenyl, or o,p-difluorophenyl;, W is hydrogen, F, Cl, Br, alkyl, alkoxy, NH2, NHCH3;, A is CH, CF, CCl, COCH3, C-CH3, C-CN or N; or, A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five or six membered ring which may contain oxygen or a double bond, and which may have attached thereto R8 which is methyl or methylene; and, R2 is wherein R3, R4, R5, R6, R7, R9, R10 and R25 are each independently H, CH3, CH2NH2, CH2NHCH3 or CH2NHC2H5, and R5, R6, R7, and R9 may also independently be NH2, NHCH3 or NHC2H5.